High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma

Clinical Biochemistry

Volumn 47, Issue 18, 2014, Pages 340-343

  Ishige, Takayuki ^a,b   Itoga, Sakae ^b   Sato, Kenichi ^c   Kitamura, Kouichi ^a,b   Nishimura, Motoi ^a,b   Sawai, Setsu ^a,b   Matsushita, Kazuyuki ^a,b   Suzuki, Kazufumi ^a   Ota, Satoshi ^a,b   Miyauchi, Hideaki ^a   Matsubara, Hisahiro ^a   Nakatani, Yukio ^a,b   Nomura, Fumio ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Anti EGFR treatment; Colorectal carcinoma; Extended RAS; High resolution melting

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; RAS PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; EXON; GENE FREQUENCY; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; WILD TYPE; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DNA DENATURATION; GENETIC SCREENING; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; REPRODUCIBILITY;

COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; GENETIC TESTING; HUMANS; MUTATION; NUCLEIC ACID DENATURATION; OUTCOME ASSESSMENT (HEALTH CARE); POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS;

EID: 84921405199     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.09.013     Document Type: Article

References (15)

1. Downward J. Targeting RAS, signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22.
2. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004, 91:355-358.
3. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
4. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
5. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
6. Dahabreh I.J., Terasawa T., Castaldi P.J., Trikalinos T.A. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011, 154:37-49.
7. Douillard J.Y., Oliner K.S., Siena S., Tabernero J., Burkes R., Barugel M., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369:1023-1034.
8. Peeters M., Oliner K.S., Parker A., Siena S., Van Cutsem E., Huang J., et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013, 19:1902-1912.
9. Schwartzberg L.S., Rivera F., Karthaus M., Fasola G., Canon J.L., Hecht J.R., et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014, 32:2240-2247.
10. Van Cutsem E., Köhne C.H., Láng I., Folprecht G., Nowacki M.P., Cascinu S., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
11. Krypuy M., Newnham G.M., Thomas D.M., Conron M., Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006, 6:295.
12. Pichler M., Balic M., Stadelmeyer E., Ausch C., Wild M., Guelly C., et al. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009, 11:140-147.
13. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
14. Vaughn C.P., Zobell S.D., Furtado L.V., Baker C.L., Samowitz W.S. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011, 50:307-312.
15. Shackelford R.E., Whitling N.A., McNab P., Japa S., Coppola D. KRAS testing: a tool for the implementation of personalized medicine. Genes Cancer 2012, 3:459-466.